BACKGROUND: Risk factors associated with preeclampsia in HIV-infected women remain largely unknown. Systemic angiogenic imbalance contributes to preeclampsia in HIV-uninfected women, but changes in angiogenic markers after highly active antiretroviral therapy (HAART) initiation have not been studied. METHODS: The Mma Bana study randomized 560 HIV-infected, HAART-naive pregnant women with CD4 counts ≥ 200 cells per cubic millimeter between 26 and 34 weeks gestation tolopinavir/ritonavir/zidovudine/lamivudine or abacavir/zidovudine/lamivudine. Another 170 participants with CD4 counts less than 200 cells per cubic millimeter initiated nevirapine/zidovudine/lamivudine between 18 and 34 weeks gestation. Characteristics of 11 women who developed preeclampsia were compared with the remaining 722 Mma Bana participants who delivered using logistic regression. Plasma samples drawn at HAART initiation and 1 month later from 60 women without preeclampsia and at HAART initiation for all 11 preeclamptic women were assayed for placental growth factor (PlGF) and soluble FMS toll-like tyrosine kinase-1 (sFlt-1). RESULTS:Pre-HAART viral load greater than 100,000 copies per milliliter was associated with preeclampsia (odds ratio: 5.8, 95% confidence interval: 1.8 to 19.4, P = 0.004). Median pre-HAART PlGF level was lower and sFlt-1 was higher in women who developed preeclampsia vs those who did not (130 vs 992 pg/mL, P = 0.001; 17.5 vs 9.4 pg/mL, P = 0.03, respectively). In multivariate analysis, PlGF and viral load remained significantly associated with preeclampsia. No significant changes in angiogenic factors were noted after 1 month of HAART treatment among non-preeclamptic women. CONCLUSIONS:Pre-HAART viral load greater than 100,000 copies per milliliter and PlGF predicted preeclampsia among women starting HAART in pregnancy. Among non-preeclamptic women, HAART treatment did not significantly alter levels of PlGF or sFlt-1 after 1 month of treatment.
RCT Entities:
BACKGROUND: Risk factors associated with preeclampsia in HIV-infectedwomen remain largely unknown. Systemic angiogenic imbalance contributes to preeclampsia in HIV-uninfectedwomen, but changes in angiogenic markers after highly active antiretroviral therapy (HAART) initiation have not been studied. METHODS: The Mma Bana study randomized 560 HIV-infected, HAART-naive pregnant women with CD4 counts ≥ 200 cells per cubic millimeter between 26 and 34 weeks gestation to lopinavir/ritonavir/zidovudine/lamivudine or abacavir/zidovudine/lamivudine. Another 170 participants with CD4 counts less than 200 cells per cubic millimeter initiated nevirapine/zidovudine/lamivudine between 18 and 34 weeks gestation. Characteristics of 11 women who developed preeclampsia were compared with the remaining 722 Mma Bana participants who delivered using logistic regression. Plasma samples drawn at HAART initiation and 1 month later from 60 women without preeclampsia and at HAART initiation for all 11 preeclamptic women were assayed for placental growth factor (PlGF) and soluble FMS toll-like tyrosine kinase-1 (sFlt-1). RESULTS: Pre-HAART viral load greater than 100,000 copies per milliliter was associated with preeclampsia (odds ratio: 5.8, 95% confidence interval: 1.8 to 19.4, P = 0.004). Median pre-HAART PlGF level was lower and sFlt-1 was higher in women who developed preeclampsia vs those who did not (130 vs 992 pg/mL, P = 0.001; 17.5 vs 9.4 pg/mL, P = 0.03, respectively). In multivariate analysis, PlGF and viral load remained significantly associated with preeclampsia. No significant changes in angiogenic factors were noted after 1 month of HAART treatment among non-preeclamptic women. CONCLUSIONS: Pre-HAART viral load greater than 100,000 copies per milliliter and PlGF predicted preeclampsia among women starting HAART in pregnancy. Among non-preeclamptic women, HAART treatment did not significantly alter levels of PlGF or sFlt-1 after 1 month of treatment.
Authors: Lars J Vatten; Anne Eskild; Tom I L Nilsen; Stig Jeansson; Pål A Jenum; Anne Cathrine Staff Journal: Am J Obstet Gynecol Date: 2007-03 Impact factor: 8.661
Authors: Natasha Parekh; Heather Ribaudo; Sajini Souda; Jennifer Chen; Mompati Mmalane; Kathleen Powis; Max Essex; Joseph Makhema; Roger L Shapiro Journal: Int J Gynaecol Obstet Date: 2011-07-20 Impact factor: 3.561
Authors: Athar H Siddiqui; Roxanna A Irani; Sean C Blackwell; Susan M Ramin; Rodney E Kellems; Yang Xia Journal: Hypertension Date: 2009-12-07 Impact factor: 10.190
Authors: Richard J Levine; Chun Lam; Cong Qian; Kai F Yu; Sharon E Maynard; Benjamin P Sachs; Baha M Sibai; Franklin H Epstein; Roberto Romero; Ravi Thadhani; S Ananth Karumanchi Journal: N Engl J Med Date: 2006-09-07 Impact factor: 91.245
Authors: Tabassum Firoz; Harshad Sanghvi; Mario Merialdi; Peter von Dadelszen Journal: Best Pract Res Clin Obstet Gynaecol Date: 2011-05-17 Impact factor: 5.237
Authors: P Stratton; R E Tuomala; R Abboud; E Rodriguez; K Rich; J Pitt; C Diaz; H Hammill; H Minkoff Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1999-02-01
Authors: Robert W Powers; Arun Jeyabalan; Rebecca G Clifton; Peter Van Dorsten; John C Hauth; Mark A Klebanoff; Marshall D Lindheimer; Baha Sibai; Mark Landon; Menachem Miodovnik Journal: PLoS One Date: 2010-10-11 Impact factor: 3.240
Authors: Juan Burgos-Soto; Eric Balestre; Albert Minga; Samuel Ajayi; Adrien Sawadogo; Marcel D Zannou; Valériane Leroy; Didier K Ekouevi; François Dabis; Renaud Becquet Journal: J Acquir Immune Defic Syndr Date: 2014-10-01 Impact factor: 3.731
Authors: Tamil Kendall; Isabella Danel; Diane Cooper; Sophie Dilmitis; Angela Kaida; Athena P Kourtis; Ana Langer; Ilana Lapidos-Salaiz; Eva Lathrop; Allisyn C Moran; Hannah Sebitloane; Janet M Turan; D Heather Watts; Mary Nell Wegner Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: Joyce L Browne; Kerstin Klipstein-Grobusch; Maria P H Koster; Dhivya Ramamoorthy; Edward Antwi; Idder Belmouden; Arie Franx; Diederick E Grobbee; Peter C J I Schielen Journal: PLoS One Date: 2016-08-17 Impact factor: 3.240